Finepoint Capital LP
Finepoint Capital LP reported 6 US-listed holdings worth $461.0 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: Qxo Inc. (67.9%), Rxo, Inc. (32.0%) and Aleanna Inc. (0.0%). Against the quarter before, it opened 0 positions, added to 1, trimmed 1 and sold out of 0.
The 6 largest of its 6 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +41.5% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Added to 1
- Qxo Inc. QXO+4.3 million shares · +31%
Trimmed 1
- Rxo, Inc. RXO-4.7 million shares · -47%
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Qxo Inc. QXO | 18.1M | $313.0 million | 67.89% | +4.3M |
| Rxo, Inc. RXO | 5.4M | $147.8 million | 32.05% | -4.7M |
| Aleanna Inc. ANNAW | 490.0K | $147,000 | 0.03% | no change |
| Aleanna Inc. ANNA | 27.7K | $80,379 | 0.02% | no change |
| Moneyhero Limited MNYWW | 895.0K | $36,964 | 0.01% | no change |
| Calidi Biotherapeutics Inc. CLDI | 1.0K | $177 | 0.00% | no change |
Read more
Change is shares against its 13F for the quarter before.Options it reported
| Company | Option | Shares under the options | Value of those shares |
|---|---|---|---|
| SPDR S&P 500 SPY | Puts | 1.7M | $1.28 billion |
| Microsoft Corp. MSFT | Calls | 1.6M | $592.1 million |
| Invesco QQQ Trust QQQ | Puts | 634.8K | $467.4 million |
3 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.